JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76

Benzinga Newsdesk www.benzinga.com Positive 86.4%

Neg 0% Neu 0% Pos 86.4%

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $72 to $76.